Optimising Accuracy And Cost-Effectiveness Of Screening For Pulmonary Arterial Hypertension In Scleroderma
Funder
National Health and Medical Research Council
Funding Amount
$375,403.00
Summary
Scleroderma is one of the most devastating diseases of the immune system. With features that affect every organ in the body, scleroderma shortens the average patient’s life by over three decades. Pulmonary arterial hypertension (PAH), a condition of increased resistance in the blood vessels of the lungs, is the major cause of death in this disease. The purpose of this project is to develop a new 'screening' model for the early detection of PAH in scleroderma, thereby enabling earlier initiation ....Scleroderma is one of the most devastating diseases of the immune system. With features that affect every organ in the body, scleroderma shortens the average patient’s life by over three decades. Pulmonary arterial hypertension (PAH), a condition of increased resistance in the blood vessels of the lungs, is the major cause of death in this disease. The purpose of this project is to develop a new 'screening' model for the early detection of PAH in scleroderma, thereby enabling earlier initiation of life-saving treatment.Read moreRead less
Risk Factors For The Development Of Pulmonary Arterial Hypertension In Systemic Sclerosis: A Prospective Cohort Study
Funder
National Health and Medical Research Council
Funding Amount
$87,199.00
Summary
I am a rheumatologist treating systemic sclerosis, a life threatening illness. A serious complication is high blood pressure in the lungs, or pulmonary arterial hypertension. Unfortunately this problem is often detected too late. My goal is to be able to identify those patients who will develop this condition so that they can access life saving treatment at the earliest possible time in order to improve their quality of life and increase their chance of survival.
Improving Outcomes In Systemic Autoimmune Disease: A Collaborative And Interdisciplinary Program Of Research
Funder
National Health and Medical Research Council
Funding Amount
$425,048.00
Summary
The multi-organ autoimmune diseases ‘scleroderma’ and ‘lupus’ have a profound negative impact on quality of life and life expectancy. The overall goal of my research is to improve patient outcomes in these two diseases. My collaborative and interdisciplinary research program entails quantifying disease burden, identifying patient subsets, optimising screening for complications, developing outcome measures for use in practice and research, and trialing new therapies.
Quantifying The Burden Of Systemic Sclerosis In Australia: From Data Linkage To Patient Reported Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$81,976.00
Summary
Systemic sclerosis (SSc) is a rare autoimmune disease with the potential to cause significant physical, financial and psychosocial burden on patients, their family members and wider community. The true ‘burden’ of SSc in Australia is unknown. My study aims to quantify this burden of disease and use our results to advocate for appropriate allocation of resources with the ultimate goal of improving patient outcomes and reducing the financial and human costs of this chronic rare disease.